★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★

Checking

Stock Profile

Philip Morris International Inc. (PM) Moat Analysis

Philip Morris International Inc.

PM · New York Stock Exchange

Market cap (USD)$293.4B
SectorConsumer
IndustryTobacco
CountryUS
Data as of
Moat score
88/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Request update

Spot something outdated? Send a quick note and source so we can refresh this profile.

Overview

Philip Morris International is a global nicotine company with combustible tobacco, smoke-free products, and a very small wellness business. Marlboro brand equity supports combustible pricing despite secular volume decline. Smoke-free defensibility is stronger where IQOS proprietary consumables create installed-base demand and product-specific authorizations permit regulated claims: FDA renewed IQOS modified-risk orders in April and authorized modified-risk claims for 20 ZYN products in June 2026. H1 net revenue rose 9.8% to $21.338bn; smoke-free products excluding wellness contributed 41.7%, and PMI described its heat-not-burn volume share as around three-quarters. At July 17, 2026, exactly 1,558,613,439 common shares were outstanding. Broad retail presence and baseline tobacco compliance are not separately scored because major rivals can replicate them; wellness has no evidenced moat.

Primary segment

Combustible Tobacco

Market structure

Oligopoly

Market share

25.3% (reported)

HHI:

Coverage

3 segments · 7 tags

Updated 2026-08-23

Segments

Combustible Tobacco

International combustible tobacco (primarily cigarettes)

Revenue

57.7%

Structure

Oligopoly

Pricing

strong

Share

25.3% (reported)

Peers

BTIMOJAPAYIMBBY

Smoke-Free Products

Smoke-free nicotine products (heated tobacco systems, oral nicotine pouches, e-vapor)

Revenue

41.7%

Structure

Oligopoly

Pricing

moderate

Share

75% (reported)

Peers

BTIMOJAPAYIMBBY

Wellness & Healthcare

Consumer health and inhaled therapeutics (oral/inhaled delivery systems and prescription inhaled products)

Revenue

0.6%

Structure

Competitive

Pricing

weak

Share

Peers

Moat Claims

Combustible Tobacco

International combustible tobacco (primarily cigarettes)

H1 2026 revenue share is combustible-tobacco net revenue of $12.314bn divided by total PMI net revenue of $21.338bn. International cigarette shipment volume fell 1.9% to 294.2bn units, while Q2 category share held at 25.3%. Source: https://www.sec.gov/Archives/edgar/data/1413329/000162828026049493/pm-20260630.htm

Oligopoly

Brand Trust

Demand

Strength

Strength 4 of 5

Durability

Durability 3 of 3

Confidence

Confidence 4 of 5

Evidence

Evidence 2 of 5

Marlboro is the leading international cigarette in PMI disclosures and matched a record 11.0% category share in Q2, but plain packaging, limited marketing, and downtrading constrain the rating.

Brand Trust moat: definition, examples, and stocks

Erosion risks

  • Accelerated smoking prevalence decline
  • Downtrading to value brands or illicit products
  • Plain packaging and marketing restrictions reducing differentiation

Leading indicators

  • Net revenue per cigarette (price/mix)
  • Marlboro share of PMI cigarette volume
  • Industry volume trends in top markets

Counterarguments

  • Marketing restrictions can blunt brand reinforcement over time
  • In downturns, consumers can downtrade or quit, limiting pricing power

Smoke-Free Products

Smoke-free nicotine products (heated tobacco systems, oral nicotine pouches, e-vapor)

H1 2026 revenue share is total smoke-free net revenue of $9.024bn less $0.118bn of wellness, or $8.906bn divided by total PMI net revenue of $21.338bn. Smoke-free products were available in 109 markets at June 30, 2026. Source: https://www.sec.gov/Archives/edgar/data/1413329/000162828026049493/pm-20260630.htm

Oligopoly

Compliance Advantage

Legal

Strength

Strength 4 of 5

Durability

Durability 2 of 3

Confidence

Confidence 4 of 5

Evidence

Evidence 2 of 5

Smoke-free expansion depends on achieving regulatory authorizations and maintaining compliant commercialization; approvals can gate access to legitimate retail and limit some competitors.

Compliance Advantage moat: definition, examples, and stocks

Erosion risks

  • Stricter standards, flavor bans, or category restrictions
  • Tax equalization with cigarettes reducing switching incentives
  • Enforcement actions or authorization withdrawals

Leading indicators

  • Regulator decisions on pending PMTA/MRTP-type applications
  • Market access changes (bans introduced/lifted)
  • Relative taxation of smoke-free vs cigarettes

Counterarguments

  • Major competitors can also obtain authorizations over time
  • In many markets, smoke-free categories are banned or heavily restricted, reducing the value of approvals

Installed Base Consumables

Demand

Strength

Strength 4 of 5

Durability

Durability 3 of 3

Confidence

Confidence 4 of 5

Evidence

Evidence 1 of 5

IQOS is a device-plus-consumables system; once users adopt the device, recurring purchases of proprietary consumables monetize the installed base and raise switching friction.

Installed Base Consumables moat: definition, examples, and stocks

Erosion risks

  • Multi-homing across nicotine formats (users split spend)
  • Device commoditization and competing systems
  • Illicit/unauthorized consumables and gray-market diversion

Leading indicators

  • Estimated adult users of smoke-free products
  • HTU shipment volume and repeat purchase trends
  • Share of category volume that is illicit/non-compliant

Counterarguments

  • Switching costs may be limited; users can revert to cigarettes or switch to other nicotine products
  • Competitors can subsidize devices and promotions to win share

IP Choke Point

Legal

Strength

Strength 2 of 5

Durability

Durability 2 of 3

Confidence

Confidence 3 of 5

Evidence

Evidence 1 of 5

Proprietary heat-not-burn technology and product design, supported by a scientific/regulatory evidence base, can slow direct imitation and sustain differentiation in key markets.

IP Choke Point moat: definition, examples, and stocks

Erosion risks

  • Patent expirations and design-arounds
  • Adverse IP litigation outcomes
  • Regulatory rules that weaken platform control

Leading indicators

  • Key patent expirations / renewals
  • Competitive product parity (induction systems, user experience)
  • IP litigation and settlements

Counterarguments

  • Rivals can develop alternative heating technologies without infringing
  • Regulatory decisions, not IP, may be the primary determinant of market outcomes

Wellness & Healthcare

Consumer health and inhaled therapeutics (oral/inhaled delivery systems and prescription inhaled products)

H1 2026 revenue share is wellness net revenue of $0.118bn divided by total PMI net revenue of $21.338bn. PMI says Aspeya currently focuses primarily on oral consumer-wellness offerings; the small business has no evidenced peer-superior barrier. Source: https://www.sec.gov/Archives/edgar/data/1413329/000162828026049493/pm-20260630.htm

Competitive

Evidence

sec_filing

Marlboro, the world's best-selling international cigarette, which accounted for approximately 43% of our total 2025 cigarette shipment volume.

Direct statement of flagship brand dominance supporting brand-driven demand and premium positioning.

sec_filing

Marlboro continued to gain share (up by 0.3 percentage points) matching its record category share of 11.0%.

Current-period category evidence supports continuing consumer preference while avoiding an unqualified maximum moat score.

sec_filing

our cigarette category volume share stood at 25.3%

Q2 2026 Form 10-Q reports the category share as flat year over year despite adverse market mix.

regulation

FDA issued modified risk granted orders to Swedish Match USA, Inc. for 20 ZYN nicotine pouch products following extensive scientific review.

Product-specific authorization permits a risk-modification claim unavailable without FDA review; it is a genuine regulatory gate rather than generic compliance.

regulation

FDA issued a renewal of modified risk granted orders to Philip Morris Products S.A.

The renewed orders allow specified IQOS devices and HeatSticks to retain authorized exposure-modification claims.

Showing 5 of 8 sources.

Risks & Indicators

Erosion risks

  • Accelerated smoking prevalence decline
  • Downtrading to value brands or illicit products
  • Plain packaging and marketing restrictions reducing differentiation
  • Reputational/litigation shocks
  • Stricter standards, flavor bans, or category restrictions
  • Tax equalization with cigarettes reducing switching incentives

Leading indicators

  • Net revenue per cigarette (price/mix)
  • Marlboro share of PMI cigarette volume
  • Industry volume trends in top markets
  • Illicit trade prevalence in key geographies
  • Regulator decisions on pending PMTA/MRTP-type applications
  • Market access changes (bans introduced/lifted)

Keep the research going

Created 2025-12-31
Updated 2026-08-23

More Rankings & Systems

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.